Ignite Creation Date:
2024-05-06 @ 2:58 AM
Last Modification Date:
2024-10-26 @ 11:26 AM
Study NCT ID:
NCT02174835
Status:
COMPLETED
Last Update Posted:
2014-06-26
First Post:
2014-06-23
Brief Title:
A Phase-1 Study to Assess the Pharmacokinetics Safety and Tolerability of AVP-786 in Healthy Volunteers
Sponsor:
Avanir Pharmaceuticals
Organization:
Avanir Pharmaceuticals
Study Overview
Official Title:
A Phase 1 Single-center Randomized Open-label Study to Assess the Pharmacokinetics Safety and Tolerability of AVP-786 Deuterated d6 Dextromethorphan HydrobromideQuinidine Sulfate in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the multiple-dose pharmacokinetics PK safety and tolerability of AVP-786 deuterated d6 dextromethorphan hydrobromide DMquinidine sulfate Q in healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None